Department of Internal Medicine, Hospital Universitaro de Salamanca, Hospital Los Montalvos s/n, E-37192 Salamanca, Spain.
Rheumatology (Oxford). 2011 Aug;50(8):1414-23. doi: 10.1093/rheumatology/ker112. Epub 2011 Mar 15.
There are limited data on the long-term prognosis of microscopic polyangiitis (MPA). A systematic review was performed to estimate the survival, renal survival and relapse rates in patients with MPA.
Articles included in MEDLINE and EMBASE databases were reviewed. Randomized or non-randomized trials, cohort, case-control and cases-series studies of patients with MPA diagnosed according to Chapel Hill Consensus Conference definitions, a high rate of biopsy-confirmed diagnosis, follow-up >1 year and follow-up losses <10%. Two independent authors using a predefined questionnaire for evaluating the quality and risk of bias for each study extracted data.
Eighteen studies for MPA prognosis (n = 940) and six for MPA outcomes after transplantation (n = 65) were included. Survival rates were 77-100% at 1 year, 46-80% at 5 years and 60-80% at 10 years. Higher mortality density occurred within the first months after diagnosis. Vasculitis was the cause of death in 32-50% of patients. Relapses were detected in 19-39% of cases (median time to relapse 15-43 months). Renal graft survival was 85-94% at 1 year and 51-87% at 5 years. Age, renal involvement and immunosuppressive treatment were related to mortality. Lower relapse rate was achieved with 12 vs 6 CYC pulses.
Evidence regarding MPA prognosis is weak. MPA mortality is mainly concentrated in the first months after diagnosis. Fewer than 50% of deaths are related to MPA activity. MPA long-term prognosis is less severe, although relapses are frequent. End-stage renal failure is a frequent complication of MPA, and renal transplantation could be an effective therapy in these patients. Early diagnosis, early initiation of a tailored therapy according to risk factors and a longer follow-up of the patients are needed.
显微镜下多血管炎(MPA)的长期预后数据有限。本系统评价旨在评估 MPA 患者的生存率、肾脏存活率和复发率。
检索 MEDLINE 和 EMBASE 数据库中的文章。纳入符合 Chapel Hill 共识会议定义、活检确诊率高、随访时间>1 年且随访失访率<10%的 MPA 患者的随机或非随机试验、队列研究、病例对照研究和病例系列研究。两位作者使用预先制定的问卷评估每个研究的质量和偏倚风险,并提取数据。
纳入 18 项 MPA 预后研究(n=940)和 6 项 MPA 移植后结局研究(n=65)。1 年生存率为 77%-100%,5 年生存率为 46%-80%,10 年生存率为 60%-80%。较高的死亡率密度出现在诊断后最初几个月内。血管炎是 32%-50%患者死亡的原因。19%-39%的病例出现复发(中位复发时间 15-43 个月)。1 年时肾移植存活率为 85%-94%,5 年时为 51%-87%。年龄、肾脏受累和免疫抑制治疗与死亡率相关。与 6 个 CYC 冲击相比,12 个 CYC 冲击可降低复发率。
关于 MPA 预后的证据较弱。MPA 的死亡率主要集中在诊断后的最初几个月内。不到 50%的死亡与 MPA 活动有关。MPA 的长期预后不那么严重,尽管复发较为频繁。终末期肾衰竭是 MPA 的常见并发症,肾移植可能是这些患者的有效治疗方法。需要早期诊断,根据危险因素尽早开始个体化治疗,并对患者进行更长时间的随访。